Statement – Rx&D Applauds Government of Canada for Investing in Personalized Medicine

OTTAWA , Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams , President of Canada's Research-Based Pharmaceutical Companies (Rx&D) on the announcement by the Government of Canada today to ensure that personalized medicine will allow for more effective treatments, thus supporting our Canadian health care system in a more sustainable way.

"Canada's Research-Based Pharmaceutical Companies welcome this commitment by the Government of Canada to establish personalized medicine as the way to transform the delivery of health care to patients.

"At Rx&D, we believe that providing the right medicine with the right dose to the right patient at the right time is crucial to improving health outcomes for Canadians. With the rise of chronic disease and an aging population, all governments are grappling with unprecedented demand for health care services. It is clear that we face a collective challenge to sustain and improve our health care system where traditional approaches are no longer efficient.

"We commend the Government of Canada's commitment to engage in this work. Pharmaceutical innovation is a proven tool to help Canadians live longer, healthier, more productive lives. It is critical to the future productivity of our country, our workplaces, our communities and our citizens. Innovation is essential for "patient-centered" care.

"The development of new and more effective medicines and vaccines continues to change the face of health care in Canada . Canadians now survive life threatening illnesses and live with chronic conditions in ways not possible for previous generations.

"We applaud the Canadian Institutes of Health Research, Genome Canada and the Cancer Stem Cell Consortium for their vision and leadership to develop and implement a scientific innovation that will result in better health for Canadians."

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

See more here:
Statement - Rx&D Applauds Government of Canada for Investing in Personalized Medicine